Modelling population-level impact to inform target product profiles for childhood malaria vaccines

  • Home / Modelling population-level impact to inform target product profiles for childhood malaria vaccines

Modelling population-level impact to inform target product profiles for childhood malaria vaccines

The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot imple…

About Post Author

Medical CPD & News

The Digitalis CPD trawler searches the web for all the latest news and journals.

Privacy Preference Center

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?

Are you sure?

By disagreeing you will no longer have access to our site and will be logged out.